Antiplatelet therapy after noncardioembolic stroke: an individual patient data network meta-analysis

Background and Purpose: We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients’ demographic and clinical characteristics. Methods: We did a network meta-analysis (NMA) of data from 6 rand...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Greving, Jacoba P. (VerfasserIn) , Diener, Hans-Christoph (VerfasserIn) , Reitsma, Johannes B. (VerfasserIn) , Bath, Philip M. (VerfasserIn) , Csiba, László (VerfasserIn) , Hacke, Werner (VerfasserIn) , Kappelle, L. Jaap (VerfasserIn) , Koudstaal, Peter J. (VerfasserIn) , Leys, Didier (VerfasserIn) , Mas, Jean-Louis (VerfasserIn) , Sacco, Ralph L. (VerfasserIn) , Algra, Ale (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 10 Jun 2019
In: Stroke
Year: 2019, Jahrgang: 50, Heft: 7, Pages: 1812-1818
ISSN:1524-4628
DOI:10.1161/STROKEAHA.118.024497
Online-Zugang:Verlag, Volltext: https://doi.org/10.1161/STROKEAHA.118.024497
Verlag, Volltext: https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.118.024497
Volltext
Verfasserangaben:Jacoba P. Greving, Hans-Christoph Diener, Johannes B. Reitsma, Philip M. Bath, László Csiba, Werner Hacke, L. Jaap Kappelle, Peter J. Koudstaal, Didier Leys, Jean-Louis Mas, Ralph L. Sacco, Ale Algra, for the Cerebrovascular Antiplatelet Trialists’ Collaborative Group

MARC

LEADER 00000caa a2200000 c 4500
001 1679334891
003 DE-627
005 20230426155236.0
007 cr uuu---uuuuu
008 191022s2019 xx |||||o 00| ||eng c
024 7 |a 10.1161/STROKEAHA.118.024497  |2 doi 
035 |a (DE-627)1679334891 
035 |a (DE-599)KXP1679334891 
035 |a (OCoLC)1341248349 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Greving, Jacoba P.  |e VerfasserIn  |0 (DE-588)1078118493  |0 (DE-627)837994705  |0 (DE-576)448945002  |4 aut 
245 1 0 |a Antiplatelet therapy after noncardioembolic stroke  |b an individual patient data network meta-analysis  |c Jacoba P. Greving, Hans-Christoph Diener, Johannes B. Reitsma, Philip M. Bath, László Csiba, Werner Hacke, L. Jaap Kappelle, Peter J. Koudstaal, Didier Leys, Jean-Louis Mas, Ralph L. Sacco, Ale Algra, for the Cerebrovascular Antiplatelet Trialists’ Collaborative Group 
264 1 |c 10 Jun 2019 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 22.10.2019 
520 |a Background and Purpose: We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients’ demographic and clinical characteristics. Methods: We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results: Aspirin/dipyridamole combination (RRNMA-adj, 0.83; 95% CI, 0.74–0.94) significantly reduced the risk of vascular events compared with aspirin, as did clopidogrel (RRNMA-adj, 0.88; 95% CI, 0.78–0.98), and aspirin/clopidogrel combination (RRNMA-adj, 0.83; 95% CI, 0.71–0.96). Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, aspirin/dipyridamole combination, and clopidogrel. Net clinical benefit was similar for clopidogrel and aspirin/dipyridamole combination (RRNMA-adj, 0.99; 95% CI, 0.93–1.05). Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination compared with clopidogrel alone was higher in patients aged <65 years than it was in patients ≥65 years (RRNMA-adj, 3.9 versus 1.7). Conclusions: Results favor clopidogrel and aspirin/dipyridamole combination for long-term secondary prevention after noncardioembolic stroke or transient ischemic attack, regardless of patient characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk of major bleeding compared with other antiplatelet regimens. 
700 1 |a Diener, Hans-Christoph  |d 1951-  |e VerfasserIn  |0 (DE-588)11811901X  |0 (DE-627)079254705  |0 (DE-576)164942688  |4 aut 
700 1 |a Reitsma, Johannes B.  |e VerfasserIn  |4 aut 
700 1 |a Bath, Philip M.  |e VerfasserIn  |4 aut 
700 1 |a Csiba, László  |e VerfasserIn  |4 aut 
700 1 |a Hacke, Werner  |d 1948-  |e VerfasserIn  |0 (DE-588)12021699X  |0 (DE-627)080530346  |0 (DE-576)164358854  |4 aut 
700 1 |a Kappelle, L. Jaap  |e VerfasserIn  |4 aut 
700 1 |a Koudstaal, Peter J.  |e VerfasserIn  |4 aut 
700 1 |a Leys, Didier  |e VerfasserIn  |4 aut 
700 1 |a Mas, Jean-Louis  |e VerfasserIn  |4 aut 
700 1 |a Sacco, Ralph L.  |e VerfasserIn  |4 aut 
700 1 |a Algra, Ale  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Stroke  |d New York, NY : Association, 1970  |g 50(2019), 7, Seite 1812-1818  |h Online-Ressource  |w (DE-627)266879985  |w (DE-600)1467823-8  |w (DE-576)075145731  |x 1524-4628  |7 nnas  |a Antiplatelet therapy after noncardioembolic stroke an individual patient data network meta-analysis 
773 1 8 |g volume:50  |g year:2019  |g number:7  |g pages:1812-1818  |g extent:7  |a Antiplatelet therapy after noncardioembolic stroke an individual patient data network meta-analysis 
856 4 0 |u https://doi.org/10.1161/STROKEAHA.118.024497  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.118.024497  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20191022 
993 |a Article 
994 |a 2019 
998 |g 12021699X  |a Hacke, Werner  |m 12021699X:Hacke, Werner  |d 50000  |e 50000PH12021699X  |k 0/50000/  |p 6 
999 |a KXP-PPN1679334891  |e 3526147302 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 22.10.2019"],"person":[{"role":"aut","given":"Jacoba P.","roleDisplay":"VerfasserIn","family":"Greving","display":"Greving, Jacoba P."},{"display":"Diener, Hans-Christoph","family":"Diener","roleDisplay":"VerfasserIn","given":"Hans-Christoph","role":"aut"},{"display":"Reitsma, Johannes B.","family":"Reitsma","roleDisplay":"VerfasserIn","role":"aut","given":"Johannes B."},{"roleDisplay":"VerfasserIn","display":"Bath, Philip M.","family":"Bath","given":"Philip M.","role":"aut"},{"role":"aut","given":"László","family":"Csiba","display":"Csiba, László","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Hacke, Werner","family":"Hacke","given":"Werner","role":"aut"},{"family":"Kappelle","display":"Kappelle, L. Jaap","roleDisplay":"VerfasserIn","role":"aut","given":"L. Jaap"},{"given":"Peter J.","role":"aut","roleDisplay":"VerfasserIn","display":"Koudstaal, Peter J.","family":"Koudstaal"},{"given":"Didier","role":"aut","family":"Leys","display":"Leys, Didier","roleDisplay":"VerfasserIn"},{"family":"Mas","display":"Mas, Jean-Louis","roleDisplay":"VerfasserIn","given":"Jean-Louis","role":"aut"},{"role":"aut","given":"Ralph L.","family":"Sacco","display":"Sacco, Ralph L.","roleDisplay":"VerfasserIn"},{"given":"Ale","role":"aut","display":"Algra, Ale","family":"Algra","roleDisplay":"VerfasserIn"}],"title":[{"title":"Antiplatelet therapy after noncardioembolic stroke","subtitle":"an individual patient data network meta-analysis","title_sort":"Antiplatelet therapy after noncardioembolic stroke"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1161/STROKEAHA.118.024497"],"eki":["1679334891"]},"language":["eng"],"physDesc":[{"extent":"7 S."}],"recId":"1679334891","name":{"displayForm":["Jacoba P. Greving, Hans-Christoph Diener, Johannes B. Reitsma, Philip M. Bath, László Csiba, Werner Hacke, L. Jaap Kappelle, Peter J. Koudstaal, Didier Leys, Jean-Louis Mas, Ralph L. Sacco, Ale Algra, for the Cerebrovascular Antiplatelet Trialists’ Collaborative Group"]},"relHost":[{"title":[{"subtitle":"journal of the American Heart Association","title":"Stroke","title_sort":"Stroke"}],"note":["Gesehen am 29.06.04"],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["266879985"],"issn":["1524-4628"],"zdb":["1467823-8"]},"language":["eng"],"recId":"266879985","corporate":[{"role":"isb","display":"American Heart Association","roleDisplay":"Herausgebendes Organ"}],"part":{"year":"2019","text":"50(2019), 7, Seite 1812-1818","issue":"7","extent":"7","volume":"50","pages":"1812-1818"},"pubHistory":["1.1970 -"],"disp":"Antiplatelet therapy after noncardioembolic stroke an individual patient data network meta-analysisStroke","origin":[{"publisher":"Association ; Lippincott Williams & Wilkins","dateIssuedDisp":"1970-","publisherPlace":"New York, NY ; Philadelphia, Pa.","dateIssuedKey":"1970"}]}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"10 Jun 2019"}]} 
SRT |a GREVINGJACANTIPLATEL1020